ASRM Today discusses the latest breakthroughs in AI and reproductive medicine
In the USA, the Food and Drug Administration plans to regulate artificial intelligence and machine learning software systems as medical devices to improve the quality, consistency, and transparency of their performance across specific age, racial, and ethnic groups.
Embryology procedures do not fall under the federal regulation of “CLIA 88.” They are not tests per se; they are cell-based procedures. Likewise, many add-on procedures related to embryology, such as preimplantation genetic testing, are considered “laboratory-developed tests” and are not subject to Food and Drug Administration regulation, at present.
Should predictive artificial intelligence algorithms in reproduction be considered medical devices or laboratory-developed tests?
Certain indications surely carry a higher risk, such as medication dosage, where the consequences of mismanagement could be severe, whereas others, such as embryo selection, are noninterventional (selecting from a patient’s own embryos and the course of treatment does not change) and present little to no risk.
The AI fertility regulatory landscape is complex, involving data diversity and performance, real-world evidence, cybersecurity, and postmarket surveillance, and calls for nuance rather than painting all of “AI in fertility” with one broad, albeit well-intentioned, stoke that effectively strangles innovation.
Listen on Spotify now >> https://open.spotify.com/episode/1y7eNzE1c8rk8byzHjD6vm?si=uzcFyWb8TiabgLfnUE0P1g&nd=1